An update on the safety and efficacy of regorafenib in the treatment of solid cancers

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 11, 2014, Pages 1607-1614

  Chan, Stephen L ^a   Ma, Brigette B Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colorectal cancer; GIST; Phase I studies; Regorafenib; Renal cell cancer; Toxicity

Indexed keywords

REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

BILE DUCT CANCER; BILIARY TRACT CANCER; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOTOXICITY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ESOPHAGUS CANCER; FISTULA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART ARREST; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; MEDICATION COMPLIANCE; MEDLINE; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; SOLID TUMOR; THROMBOEMBOLISM; ANIMAL; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84911362571     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.970169     Document Type: Review

References (32)

1. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129(1):245-55 •• Important preclinical data on regorafenib in cancer models.
2. Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8(25):2269-78
3. Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2014;135(6):1487-96
4. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12(7):1322-31
5. Cyran CC, Kazmierczak PM, Hirner H, et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One 2013;8(9):e76009
6. Carr BI, Cavallini A, Lippolis C, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013;228(2):292-7
7. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18(9):2658-67 • First-in-human clinical study of regorafenib in cancer patients.
8. Trnkova Z, Grothey A, Sobrero A, et al. Population pharmacokinetics analysis of regorafenib and its active metabolites from the phase III CORRECT study of metastatic colorectal cancer. Ann Oncol 2013;24(Suppl 4):iv37
9. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012;13(10):1055-62
10. Kies M, Blumenschein G, Christensen O, et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol, 2010;28(Suppl 15):abstract 7585
11. Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013;24(6):1560-7
12. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8(3):371-82
13. Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 2014;32(1):104-12
14. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106(11):1722-7
15. Finn RS, Blumenschein G, Tolcher A, et al. Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): phase I safety and pharmacokinetic (PK) study. J Clin Oncol 2013;31(Suppl 4):abstract 300
16. Clinical Pharmacology Biopharmaceutics Review on Regorafenib (Stivarga®) by, USA Food Drug Administration, NDA 203-085. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204369Orig1s000ClinPharmR.pdf
17. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216(1):64-74
18. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24(29):4764-74
19. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302 •• Registrational study in gastrointestinal stromal tumor.
20. Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014;6(3):115-27
21. George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012;30(19):2401-7
22. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381(9863):303-12 •• Registrational study in colorectal cancer.
23. Li J, Qin S, Yau T, et al. CONCUR: a randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC). Ann Oncol 2014;25(Suppl 2):ii114-i15
24. Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013;31(4):1078-86
25. Shitara K, Yamazaki K, Uetake H, et al. Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). J Clin Oncol 2014;32(5s suppl):abstract TPS3662
26. Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013;49(16):3412-19
27. Grothey A, Van Cutsem E, Sobrero A, et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol 2013;31(Suppl 4):abstract 467
28. De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014;22(3):837-46
29. Khan G, Moss RA, Braiteh F, Saltzman M. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag Res 2014;6:93-103
30. Gomes D, Hassabo HM, Al Mutar SS, et al. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. J Clin Oncol 2014;32(Suppl 3):abstract 635
31. Maruzzo M, Kollar A, Benson CA, et al. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the U.K. Managed Access Program. J Clin Oncol 2014;32(5s Suppl):abstract 10551
32. Wang Z, Xu J, Nie W, et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70(2):225-31